Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Repligen Corporation Common Stock — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.54 (market cap $140.85M), while Repligen Corporation Common Stock trades at $180.48 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 80.3× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Repligen Corporation Common Stock for 0 Days on average.
| KOLD | RGEN | |
|---|---|---|
Market Cap | $140.85M | $11.31B |
Volume | 6,606,542 | 1,216,919 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $194.57 |
52-Week Low | $13.58 | $102.87 |
Typical Hold Time | 10 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $23.85, down 5.06% over the past 24 hours amid bearish technical signals. The stock faces pressure from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, though oversold RSI conditions suggest potential for near-term stabilization. Recent news highlights geopolitical tensions in the Middle East and domestic production trends as key market drivers.
The outlook remains challenging with fundamental data unavailable for analysis. Investment opportunities may emerge from oversold technical conditions, while risks include continued energy price volatility and geopolitical uncertainty. The bearish technical setup requires careful monitoring of support levels and energy market developments for potential reversal signals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
